Effects of Dual Sofosbuvir/Daclatasvir Therapy on Weight and Linear Growth in Adolescent Patients with Chronic Hepatitis C Virus Infection. Issue 7 (July 2019)

• Record Type: Journal Article
• Authors: Yakoot, Mostafa; El-Shabrawi, Mortada H.; AbdElgawad, Manal M.; Mahfouz, Aml A.; Khalil, Ahmed F.; Kamal, Naglaa M.; Helmy, Sherine; Abdo, Alaa M.; Kamal, Enas M.; El-Khayat, Hisham R.
• Is Part Of: Pediatric infectious disease journal. Volume 38:Issue 7(2019)
• Publication Date: 2019-07
• Subjects: chronic hepatitis C -- adolescents -- sofosbuvir -- daclatasvir -- linear growth -- weight; Communicable diseases in children -- Periodicals; Infection in children -- Periodicals; 618.929
• DOI: 10.1097/INF.0000000000002222
• Languages: English
• ISSNs: 0891-3668

Abstract

Abstract : Negative effects on growth indices had been reported in children treated with interferon for chronic viral hepatitis. Forty chronic hepatitis C virus-infected adolescents, 12–17 years of age, were treated with sofosbuvir/daclatasvir therapy for 12 weeks. The intent-to-treat sustained virologic response rate at 12 weeks after end of treatment was 39/40 (97.5%). Unlike interferon-based therapy, we did not detect significant negative effects on linear growth or weight. Contrarily, a trend to increased appetite and insignificant weight gain was observed, but further larger studies are needed to confirm. See Video-Abstract, http://links.lww.com/ASAIO/A381 . Abstract : Supplemental Digital Content is available in the text.